INSP vs RMD
INSP: Inspire Medical Systems provides a unique, neurostimulation-based alternative therapy for obstructive sleep apnea patients who struggle with traditional PAP machines. RMD: ResMed is a leading provider of AI-powered, cloud-connected medical devices and software that revolutionize the management of sleep apnea and chronic respiratory conditions at home.
Side-by-side fundamentals
| Metric | INSP | RMD | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $66.69 | $226.73 | |
| Market cap | $1.9B | $32.7B | |
| P/E as of 2026-10-08 | 14.46 | 21.73 | INSP lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2026 | n/a | 1.11 | |
| Net margin | +15.9% | +26.9% | RMD higher |
| Gross margin | +85.4% | +61.1% | INSP higher |
| Operating margin | +5.6% | +33.4% | RMD higher |
| ROE | +18.6% | +23.1% | RMD higher |
| ROA | +16.0% | +17.0% | RMD higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.10 | INSP lower |
| Revenue growth (YoY) as of 2026-09-02 | +4.3% | +9.8% | RMD higher |
| Revenue CAGR (3y) SEC XBRL | +30.8% | +10.2% | INSP higher |
| Dividend yield as of 2026-09-02 | n/a | +1.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 14 | RMD higher |
| Beta as of 2026-09-02 | 1.12 | 0.58 | |
| 1-year return as of 2026-10-08 close | -15.1% | -19.7% | INSP higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.